Nevada News Reporter

Hereditary Angioedema Market: Latest Study by DelveInsight Forecasts Remarkable Growth During the Forecast Period (2023-32) | BioCryst, KalVista, Pharvaris, BioMarin, Ionis, Shire, Takeda, CSL Behring

November 10
01:28 2023
Hereditary Angioedema Market: Latest Study by DelveInsight Forecasts Remarkable Growth During the Forecast Period (2023-32) | BioCryst, KalVista, Pharvaris, BioMarin, Ionis, Shire, Takeda, CSL Behring
Delveinsight Business Research LLP
As per DelveInsight, the Hereditary Angioedema Market is anticipated to evolve immensely in the coming years owing to the rise in the number of cases of Hereditary Angioedema and the launch of new therapies in the market.

DelveInsight’s “Hereditary Angioedema Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Hereditary Angioedema market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Hereditary Angioedema drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Hereditary Angioedema treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Hereditary Angioedema: An Overview

Hereditary Angioedema (HAE) is a rare genetic disorder caused by a deficiency in functional C1 inhibitor (C1INH) that results in recurrent attacks of localized subcutaneous or mucosal edema, most commonly affecting the skin, intestines, upper respiratory tract, and oropharynx

Hereditary Angioedema is a heterogeneous disease with complex pathophysiology that involves several pathways resulting in the increased production of bradykinin with mutations of multiple molecules in genetic etiology. These could include the Kallikrein gene mutations; Bradykinin gene or its receptor mutations; Kininase 1 gene mutations and loss of function and mutations in gene encoding aminopeptidase and ACE enzymes.

It is classified into three types based on genetic defects such as type I Hereditary Angioedema with low levels of C1-INH in the body, type II with poorly functioning C1-INH, or the recently identified types of Hereditary Angioedema with normal functioning C1-INH (formerly known as type III HAE). Identification of the novel polymorphisms in several genes leading to modification in the clinical phenotype of Hereditary Angioedema is a relatively recent phenomenon.

Hereditary Angioedema treatment has evolved with advancement in understanding the pathogenesis of this disease. It is directed towards either replacing the defective protein or blocking various molecules involved in the production of bradykinin or the bradykinin receptor. The current standard of care for Hereditary Angioedema attacks are C1 inhibitors, ecallantide, or icatibant. If these drugs are not available then attacks are being treated with solvent detergent-treated plasma (SDP) and frozen plasma.

Hereditary Angioedema Market Key Facts

  • In 2021, EU4 and the UK countries captured an estimated USD 347 million, which is expected to rise by 2032.

  • The expected launch of potential therapy may increase market size in the coming years, assisted by an increase in the diagnosed prevalent population of Hereditary Angioedema.

  • Upcoming therapy such as Garadacimab, Donidalorsen has the potential to create a significant positive shift in the Hereditary Angioedema (HAE) market size.

  • The total diagnosed prevalent cases of Hereditary Angioedema in the 7MM+China was found to be 14,375 approximately in 2021, which might increase by the end of 2032. These cases are expected to increase at a considerable CAGR during the study period (2019-2032).

  • Among the European countries, the UK had the highest diagnosed prevalent population of Hereditary Angioedema, with approximately 1,348 cases, followed by Germany, which had 1,266 diagnosed prevalent population in 2021. On the other hand, Spain and Italy had the lowest and equal number of diagnosed prevalent populations, with approximately 942 cases in 2021.

  • Japan accounted for approximately 462 diagnosed prevalent cases of Hereditary Angioedema in the year 2021 which is expected to decrease during the forecasted period (2022-2032).

Hereditary Angioedema Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Hereditary Angioedema pipeline therapies. It also thoroughly assesses the Hereditary Angioedema market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Hereditary Angioedema drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Hereditary Angioedema Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Hereditary Angioedema epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Hereditary Angioedema epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Hereditary Angioedema Epidemiology, Segmented as –

  • Total Diagnosed Prevalent Cases of Hereditary Angioedema

  • Site-specific cases of Hereditary Angioedema 

  • Type-specific cases of Hereditary Angioedema

  • Age-specific cases of Hereditary Angioedema 

  • Gender-specific cases of Hereditary Angioedema 

Hereditary Angioedema Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Hereditary Angioedema market or expected to be launched during the study period. The analysis covers the Hereditary Angioedema market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Hereditary Angioedema drugs based on their sale and market share.

The report also covers the Hereditary Angioedema pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Hereditary Angioedema companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Hereditary Angioedema Market Will Evolve and Grow by 2032 @

Hereditary Angioedema Therapeutics Analysis

Early targeted treatment of Hereditary Angioedema attacks, as well as a preventative treatment for those with frequent attacks, is the hallmark of current management of HAE. The market overall has been segmented into two treatment strategies that are commonly used for Hereditary Angioedema as on-demand therapies, which are taken to minimize the severity of angioedema symptoms and resolve symptoms as quickly as possible and further as long-term prophylaxis of attacks. Short-term (or periprocedural) prophylaxis treatment is taken before activities that are known to trigger attacks.

There are now several options available for the treatment of acute attacks, supported by robust data from clinical trials. Of the available acute treatment options, plasma-derived C1-INH such as Berinert, and recombinant C1-INH (Ruconest) is administered intravenously. In contrast, icatibant (Firazyr) and ecallantide (Kalbitor) target the contact pathway and are administered subcutaneously.

Several major pharma and biotech companies are developing therapies for Hereditary angioedema. Currently, KalVista Pharmaceuticals is leading the therapeutics market with its Hereditary angioedema drug candidates in the most advanced stage of clinical development.

Hereditary Angioedema Companies Actively Working in the Therapeutics Market Include

  • BioCryst Pharmaceuticals

  • KalVista Pharmaceuticals

  • Pharvaris

  • BioMarin Pharmaceutical

  • Ionis Pharmaceuticals, Inc.

  • Intellia Therapeutics

  • Shire

  • Takeda

  • CSL Behring

  • Pharming Group

And Many Others

Emerging and Marketed Hereditary Angioedema Therapies Covered in the Report Include:

  • Takhzyro: Takeda

  • Firazyr: Shire/Takeda

  • Cinryze: Shire/Takeda

  • Kalbitor: Shire/Takeda

  • Haegarda: CSL Behring

  • Berinert: CSL Behring

  • Ruconest: Pharming Group

  • BCX7353: BioCryst Pharmaceuticals

  • IONIS-PKK-LRx: Ionis Pharmaceuticals

  • KVD900: KalVista Pharmaceuticals

  • CSL312: CSL Behring

And Many More

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Hereditary Angioedema Competitive Intelligence Analysis

4. Hereditary Angioedema Market Overview at a Glance

5. Hereditary Angioedema Disease Background and Overview

6. Hereditary Angioedema Patient Journey

7. Hereditary Angioedema Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Hereditary Angioedema Treatment Algorithm, Current Treatment, and Medical Practices

9. Hereditary Angioedema Unmet Needs

10. Key Endpoints of Hereditary Angioedema Treatment

11. Hereditary Angioedema Marketed Therapies

12. Hereditary Angioedema Emerging Drugs and Latest Therapeutic Advances

13. Hereditary Angioedema Seven Major Market Analysis

14. Attribute Analysis

15. Hereditary Angioedema Market Outlook (In US, EU5, and Japan)

16. Hereditary Angioedema Companies Active in the Market

17. Hereditary Angioedema Access and Reimbursement Overview

18. KOL Views on the Hereditary Angioedema Market

19. Hereditary Angioedema Market Drivers

20. Hereditary Angioedema Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @



About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Choroidal Neovascularization Market

“Choroidal Neovascularization Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Choroidal Neovascularization market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Choroidal Neovascularization market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States